

# PB 41 of 2025

# National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 4)

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated 28 April 2025

### REBECCA RICHARDSON

Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division

Conter	nts		
	1	Name	]
	2	Commencement	]
	3	Authority	
	4	Schedules	]
Schedule	1—Amo	endments	2
	Vational H PB 120 of	ealth (Pharmaceutical benefits—early supply) Instrument 2015 2015).	2

### 1 Name

- (1) This instrument is the *National Health (Pharmaceutical benefits early supply) Amendment Instrument 2025 (No. 4).*
- (2) This instrument may also be cited as PB 41 of 2025.

### 2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information						
Column 1	Column 2	Column 3				
Provisions	Commencement	Date/Details				
1. The whole of this instrument	1 May 2025	1 May 2025				

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

# 3 Authority

This instrument is made under subsection 84AAA(2) of the National Health Act 1953.

## 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

# Schedule 1—Amendments

# National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

# [1] Schedule 1, after entry for Donepezil in the form Tablet containing donepezil hydrochloride 10 mg

insert:

Drospirenone Pack containing 24 tablets 4 mg and 4 inert tablets 20 4 2	
---	--

### [2] Schedule 1, entry for Pirfenidone in the form Tablet 801mg

omit from the column headed "Form": Tablet 801mg

substitute: Tablet 801 mg

# [3] Schedule 1, after entry for Pramipexole in the form Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg

insert:

Prasugrel	Tablet 5 mg	20	28	5
	Tablet 10 mg	20	28	5

## [4] Schedule 1, entry for Prazosin

insert as first entry:

Prazosin Capsule 1 mg (as hydrochloride) (S19A) 20 100 5
--

# [5] Schedule 1, after entry for Reboxetine

insert:

Relugolix with estradiol and with	Tablet containing relugolix 40 mg with estradiol (as hemihydrate) 1 mg	20	28	5	
norethisterone	and with norethisterone acetate 500 micrograms				

# [6] Schedule 2, entry for Prazosin

insert as first entry:

Prazosin Capsule 1 mg (as hydrochloride) (S19A)	50	200	5	
---	----	-----	---	--